Flupentixol%25252525252525252520and%25252525252525252520melitracen

# Flupentixol and Melitracen ## Overview Flupentixol/melitracen is a fixed-dose combination psychotropic agent. Flupentixol is a thioxanthene antipsychotic (dopamine receptor antagonist) used here in low doses for anxiolytic/antidepressant effects, while melitracen is a tricyclic antidepressant (TCA). ## Primary Indications * Management of mild to moderate anxiety, depression, and apathy. * Psychosomatic disorders accompanied by anxiety and apathy. * *Note: Not indicated for major depressive disorder with psychotic features.* ## Adult Dosing Standard maintenance dose is 1 tablet (0.5 mg flupentixol / 10 mg melitracen) twice daily (morning and noon). * **Maximum Dose:** 4 tablets daily. * Doses should be avoided in the late afternoon/evening to prevent insomnia. ## Pediatric Dosing **Not established.** Safety and efficacy in children and adolescents under 18 years have not been adequately studied. Use is generally contraindicated or not recommended in pediatric populations. ## Dose Adjustments * **Geriatric:** Use with extreme caution; start with the lowest possible dose (e.g., 1 tablet daily). Sensitive to anticholinergic and extrapyramidal effects. * **Renal/Hepatic Impairment:** Reduce dose or increase dosing interval. Use with caution in hepatic impairment due to extensive metabolism. ## Contraindications * Hypersensitivity to any component. * Recent myocardial infarction or cardiac conduction defects (arryhthmias, heart block). * Acute phase of recovery post-MI. * Severe CNS depression (alcohol, barbiturate, or opiate intoxication). * Blood dyscrasias. * Narrow-angle glaucoma. * Prostatic hypertrophy with urinary retention. ## Adverse Effects * **Common:** Dry mouth, insomnia, restlessness/akathisia, dizziness, tremor, blurred vision, constipation. * **Serious:** Extrapyramidal symptoms (at higher cumulative doses), QT interval prolongation, urinary retention, tardive dyskinesia, and neuroleptic malignant syndrome (rarely reported). ## Key Drug Interactions * **CNS Depressants:** Enhances effects of alcohol, barbiturates, and opiates. * **MAO Inhibitors:** Risk of serotonin syndrome or hypertensive crisis; discontinue MAOIs at least 14 days prior to starting. * **Antihypertensives:** May antagonize the effect of guanethidine or similar agents. * **QT Prolonging Agents:** Additive risk of arrhythmias with other agents (e.g., citalopram, ondansetron). ## Monitoring * **Cardiovascular:** Baseline and periodic ECGs, especially in the elderly or those with cardiac risk factors. * **Neurological:** Monitor for movement disorders (akathisia, tremors). * **Hepatic:** Periodic LFT monitoring for chronic therapy. * **Ophthalmologic:** Monitor for symptoms of increased intraocular pressure. ## Clinical Pearls * The stimulant-like effect of melitracen can cause significant insomnia if taken after midday. * The combination is often marketed for "functional" disorders; avoid long-term use (typically limited to 3-6 months) to mitigate the risk of tardive dyskinesia and drug dependence. * Tapering is required upon discontinuation to avoid withdrawal symptoms (e.g., nausea, irritability, malaise). *** **Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Prescribing practices vary by region and individual patient presentation. Always verify the most current labeling, local guidelines, and official prescribing information from the manufacturer before administering or prescribing this medication.